Cyclacel Pharmaceuticals Inc [NASDAQ: CYCC] surged by $0.04 during the normal trading session on while it closed the day at $0.45.
Cyclacel Pharmaceuticals Inc stock has also gained 8.41% of its value over the past 7 days. However, CYCC stock has declined by -65.91% in the 3 months of the year. Over the past six months meanwhile, it has lost -81.56% and lost -83.15% year-on date.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for CYCC stock reached $0.97 million, with 2.15 million shares outstanding and 2.06 million shares in the current float. Compared to the average trading volume of 1.19M shares, CYCC reached a trading volume of 12616964 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Cyclacel Pharmaceuticals Inc [CYCC]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CYCC shares is $1.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CYCC stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Cyclacel Pharmaceuticals Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on July 18, 2022. While these analysts kept the previous recommendation, ROTH Capital raised their target price to Buy. The new note on the price target was released on April 27, 2020, representing the official price target for Cyclacel Pharmaceuticals Inc stock.
The Average True Range (ATR) for Cyclacel Pharmaceuticals Inc is set at 0.16, with the Price to Sales ratio for CYCC stock in the period of the last 12 months amounting to 12.07. The Price to Book ratio for the last quarter was 0.81, with the Price to Cash per share for the same quarter was set at 2.80.
CYCC stock trade performance evaluation
Cyclacel Pharmaceuticals Inc [CYCC] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 8.41. With this latest performance, CYCC shares dropped by -44.68% in over the last four-week period, additionally sinking by -81.56% over the last 6 months – not to mention a drop of -94.24% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CYCC stock in for the last two-week period is set at 33.76, with the RSI for the last a single of trading hit 32.99, and the three-weeks RSI is set at 34.68 for Cyclacel Pharmaceuticals Inc [CYCC]. The present Moving Average for the last 50 days of trading for this stock 0.8737, while it was recorded at 0.4431 for the last single week of trading, and 1.6926 for the last 200 days.
Cyclacel Pharmaceuticals Inc [CYCC]: An insightful look at the core fundamentals
Cyclacel Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.07 and a Current Ratio set at 1.07.
Cyclacel Pharmaceuticals Inc [CYCC]: Institutional Ownership
There are presently around $18.03%, or 18.94%% of CYCC stock, in the hands of institutional investors.
